EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Add-on of anti-PD-1 therapy to BRAF/MEK inhibition in patients with poor-prognosis stage IV BRAFV600-mutant melanoma, a retrospective case series

C. Bertels, D. Talhaoui, I. Dirven, B. Neyns

EJC Skin Cancer · 2026 · 4 · 100795

DOI: 10.1016/j.ejcskn.2026.100795 ↗

Kurz gefasst

Fachartikel in der Zeitschrift EJC Skin Cancer, 2026. Verfasst von C. Bertels und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Bertels, C., Talhaoui, D., Dirven, I., & Neyns, B. (2026). Add-on of anti-PD-1 therapy to BRAF/MEK inhibition in patients with poor-prognosis stage IV BRAFV600-mutant melanoma, a retrospective case series. EJC Skin Cancer, 4, 100795. https://doi.org/10.1016/j.ejcskn.2026.100795

Vancouver

Bertels C, Talhaoui D, Dirven I, Neyns B. Add-on of anti-PD-1 therapy to BRAF/MEK inhibition in patients with poor-prognosis stage IV BRAFV600-mutant melanoma, a retrospective case series. EJC Skin Cancer. 2026;4:100795. doi:10.1016/j.ejcskn.2026.100795

BibTeX
@article{Bertels2026,
  author = {Bertels, C. and Talhaoui, D. and Dirven, I. and Neyns, B.},
  title = {Add-on of anti-PD-1 therapy to BRAF/MEK inhibition in patients with poor-prognosis stage IV BRAFV600-mutant melanoma, a retrospective case series},
  journal = {EJC Skin Cancer},
  year = {2026},
  volume = {4},
  pages = {100795},
  doi = {10.1016/j.ejcskn.2026.100795}
}
Kostenlos starten →